(Boston)--Proper lung function relies on the precise balance of specialized epithelial cells (cells that line the surfaces of the body) that coordinate functions to maintain homeostasis. One important lung cell type is the goblet cell, which secretes mucus that helps protect the lining of the bronchus (major air passages of the lung) and trap microorganisms. Goblet cells are often increased in lung diseases, but signals that lead to their dysregulation are not well understood.
Researchers have now discovered a new set of signals that control the production of goblet cells in the lung. "By altering the proteins that control these signals we are able to either increase or decrease the production of goblet cells which offers potential new avenues for therapeutically targeting goblet cells in lung disease," explained corresponding author Bob (Xaralabos) Varelas, PhD, associate professor of biochemistry at Boston University School of Medicine.
The researchers used an experimental model carrying a genetic deletion of Yap and Taz, which are genes that encode proteins that control an important signaling network in the lung. They compared the genetic deletion model with a "control" model and found that the Yap/Taz deletion model had severe lung damage and elevated goblet cell number that was associated with increased mucin production.
In order to understand how loss of Yap/Taz led to increased goblet cell numbers, the researchers isolated cells from the experimental model and human lungs and cultured them in the lab. They then used gene expression and chromatin binding analyses to discover how these proteins control a network of genes important for mucus production. Finally, they used these cells in the lab to test inhibitors of goblet cell differentiation and mucus production.
According to the researchers, several lung diseases exhibit an expansion of goblet cells including asthma, COPD, Cystic Fibrosis and chronic bronchitis. "By identifying new regulators of goblet cell production, we offer insight into mechanisms that may contribute to these diseases. By targeting these signals we can repress the production and maintenance of goblet cells and therefore may offer therapeutic directions for limiting the expansion of these cells in lung disease," said Varelas.
These findings appear online in the journal Cell Reports.
This work was supported by the Boston University Sequencing Core and Flow Cytometry Core and by BU-CTSI grant UL1TR001430. XV was funded by NIH/NHLBI R01HL124392 and NIH/NICHD R21HD094012 and by an ACS Research Scholar Grant (RSG-17-138-01-CSM). J.H.-B. was funded Q12 by NIH/NHLBI grants F31HL132506 and T32 HL007035. S.M. was in part funded by Find the Cause Breast Cancer Foundation. A.F. and B.N. were funded by Moorman-Simon Fellowships in Computational Biomedicine.
Note to Editor:X.V and J.B. were supported in part by a Janssen Pharmaceuticals Sponsored Research Agreement. The remaining authors declare no competing interests.